An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

Seven different postoperative complications occurred two to four times more often in patients who had a history of intravitreal drug injections as compared with those who did not. Among complications ...

New study from University of California, Irvine and University of California, Santa Barbara researchers demonstrates improved retinal function and vascular integrity, supporting further investigation ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...

TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced that aflibercept 8 mg and EYLEA® (aflibercept) Injection ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Retinal vascular obstruction is an eye disease that causes vision loss by clogging blood vessels that supply nutrition and oxygen to the retina. According to the Health Insurance Review and Assessment ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron ...